A Study of GC101 TIL in Advanced Melanoma

Trial Details

NCT ID

NCT06703398

Phase

PHASE2

Sponsor

Shanghai Juncell Therapeutics

Status

RECRUITING

Cancer Type

Melanoma

Interventions

• GC101 TIL
• dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin

Locations (sample)

• Beijing, China|39.9075,116.39723

Key Eligibility Criteria

• Signed the informed consent form (ICF) and able to comply with the visits and related procedures specified in the protocol;
• Aged ≥18 years and ≤75 years, regardless of gender;
• Patients with unresectable advanced, recurrent or metastatic melanoma (excluding uveal melanoma) ;
• Patients who have failed or resisted to PD-1 antibodies；

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.